Pure Financial Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.41M Buy
7,010
+2,026
+41% +$2.07M 0.11% 90
2026
Q1
$4.58M Buy
4,984
+515
+12% +$522K 0.07% 117
2025
Q4
$4.8M Buy
4,469
+149
+3% +$142K 0.07% 112
2025
Q3
$3.3M Sell
4,320
-194
-4% -$144K 0.05% 129
2025
Q2
$3.52M Buy
4,514
+641
+17% +$498K 0.06% 123
2025
Q1
$3.2M Buy
3,873
+466
+14% +$388K 0.07% 105
2024
Q4
$2.63M Buy
3,407
+1,058
+45% +$876K 0.06% 101
2024
Q3
$2.08M Sell
2,349
-2,935
-56% -$2.64M 0.05% 115
2024
Q2
$4.78M Sell
5,284
-115
-2% -$92K 0.13% 73
2024
Q1
$4.2M Buy
5,399
+1,027
+23% +$731K 0.13% 77
2023
Q4
$2.55M Sell
4,372
-130
-3% -$75.9K 0.09% 99
2023
Q3
$2.42M Buy
4,502
+734
+19% +$378K 0.1% 90
2023
Q2
$1.77M Sell
3,768
-11
-0.3% -$4.61K 0.08% 99
2023
Q1
$1.3M Sell
3,779
-222
-6% -$74.9K 0.06% 108
2022
Q4
$1.46M Buy
4,001
+44
+1% +$15.6K 0.08% 100
2022
Q3
$1.28M Buy
3,957
+184
+5% +$58.3K 0.07% 98
2022
Q2
$1.22M Buy
3,773
+696
+23% +$209K 0.08% 105
2022
Q1
$881K Buy
3,077
+247
+9% +$63.6K 0.04% 114
2021
Q4
$782K Buy
2,830
+56
+2% +$14.2K 0.04% 109
2021
Q3
$641K Buy
2,774
+262
+10% +$64.7K 0.05% 116
2021
Q2
$577K Hold
2,512
0.05% 127
2021
Q1
$469K Hold
2,512
0.05% 123
2020
Q4
$424K Hold
2,512
0.05% 124
2020
Q3
$372K Hold
2,512
0.05% 113
2020
Q2
$412K Buy
2,512
+8
+0.3% +$1.23K 0.06% 99
2020
Q1
$347K Sell
2,504
-204
-8% -$28K 0.06% 101
2019
Q4
$356K Buy
2,708
+204
+8% +$23.6K 0.06% 107
2019
Q3
$280K Sell
2,504
-234
-9% -$26.1K 0.05% 115
2019
Q2
$303K Sell
2,738
-386
-12% -$45.5K 0.05% 113
2019
Q1
$405K Buy
3,124
+11
+0.4% +$1.34K 0.08% 95
2018
Q4
$360K Sell
3,113
-53
-2% -$5.92K 0.07% 99
2018
Q3
$340K Buy
+3,166
New +$317K 0.07% 109
2017
Q4
Sell
-2,395
Closed -$205K 59
2017
Q3
$205K Buy
+2,395
New +$196K 0.05% 108
2016
Q3
Sell
-2,731
Closed -$215K 97
2016
Q2
$215K Buy
+2,731
New +$206K 0.07% 88

Other funds holding LLY

Pure Financial Advisors's LLY Position: Q2 2026 in Review

Pure Financial Advisors increased its Eli Lilly (LLY) stake by 41% in Q2 2026, buying an estimated $2.07M and bringing the position to 7,010 shares worth $8.41M. The position accounts for 0.11% of the portfolio, ranked #90.

Pure Financial Advisors first reported a position in LLY in Q2 2016 and has held it in 34 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Pure Financial Advisors held 7,010 shares of Eli Lilly worth $8.41M as of Q2 2026.
  • Pure Financial Advisors bought 2,026 Eli Lilly shares in Q2 2026, an estimated $2.07M.
  • Eli Lilly made up 0.11% of Pure Financial Advisors's portfolio in Q2 2026, its #90 holding.
  • Pure Financial Advisors first reported a position in Eli Lilly in Q2 2016 and has held it in 34 quarters since.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Pure Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.